Compare SOPA & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | XBIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.9M |
| IPO Year | 2021 | N/A |
| Metric | SOPA | XBIO |
|---|---|---|
| Price | $3.14 | $2.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 33.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,227,427.00 | $2,858,935.00 |
| Revenue This Year | $26.32 | $1.99 |
| Revenue Next Year | $13.64 | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.65 | ★ 13.30 |
| 52 Week Low | $0.64 | $1.90 |
| 52 Week High | $6.75 | $13.93 |
| Indicator | SOPA | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 40.14 |
| Support Level | $2.41 | $1.95 |
| Resistance Level | $4.46 | $2.29 |
| Average True Range (ATR) | 0.67 | 0.14 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 61.03 | 51.16 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.